BHCM
PLRX icon

Brevan Howard Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Brevan Howard Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,260
Closed -$115K – 1352
2024
Q3 		$115K Buy
+10,260
New +$128K ﹤0.01% 1062

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Brevan Howard Capital Management's PLRX Position: Q4 2024 in Review

Brevan Howard Capital Management sold out of Pliant Therapeutics (PLRX) in Q4 2024, closing a stake of 10,260 shares — an estimated $115K sold.

Brevan Howard Capital Management first reported a position in PLRX in Q3 2024 and held it in 1 quarter. The position peaked at $115K in Q3 2024. 160 funds tracked by Wall St. Rank hold PLRX as of Q4 2024.

  • Brevan Howard Capital Management reported no remaining Pliant Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,260 Pliant Therapeutics shares in Q4 2024, an estimated $115K.
  • Brevan Howard Capital Management first reported a position in Pliant Therapeutics in Q3 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Pliant Therapeutics position peaked at $115K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2024.

Based on Brevan Howard Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.